The raised guidance and double-digit Royalty Receipts growth signal continued momentum in the core royalty portfolio. Watch for further R&D co-funding deals (J&J, Teva) and clinical catalysts (daraxonrasib pancreatic cancer data, Ziihera PDUFA date Aug 25, 2026) that could drive incremental upside to Portfolio Receipts.
Price Chart
Executive Summary
Royalty Pharma reported Q1 2026 Portfolio Receipts of $925M (+10% YoY) and Royalty Receipts of $887M (+13% YoY), driven by Tremfya, Voranigo, and Evrysdi. The company raised full-year 2026 Portfolio Receipts guidance to $3.325B-$3.450B (from $3.275B-$3.425B), reflecting expected Royalty Receipts growth of 4%-8%. Net cash from operations was $718M, up 20% YoY, and the company deployed $528M in capital during the quarter.
Key Financial Metrics
Key Facts
- Portfolio Receipts grew 10% YoY to $925M in Q1 2026
- Royalty Receipts grew 13% YoY to $887M
- Raised full-year 2026 Portfolio Receipts guidance to $3.325B-$3.450M (from $3.275B-$3.425B)
- Net cash from operations of $718M, up 20% YoY
- Adjusted EBITDA (non-GAAP) of $889M, up 21% YoY
- Portfolio Cash Flow (non-GAAP) of $722M, up 18% YoY
- Announced up to $1.25B in new royalty transactions in Q1
- Recorded $69M non-cash impairment charge related to Tazverik
- Repurchased 1.1M shares for $50M in Q1
Financial Impact
Portfolio Receipts guidance raised by $50M at midpoint; Royalty Receipts growth of 4-8% expected for FY2026
Risk Factors
- Promacta revenue declined 61% YoY due to generic competition
- Tazverik withdrawal and $69M impairment charge
- Potential for further generic erosion in the portfolio
- Interest expense increased to $94M from $65M YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001802768-26-000008 |
| Document: 0001802768-26-000008-index.html | 0001802768-26-000008 |
| Document: 0001802768-26-000008.txt | 0001802768-26-000008 |
| 8-K Data (Synthetic) | 0001802768-26-000008 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Press Release | $60.59 $58.47 | ▲ +3.50% | ▲ +2.38% | $57.16 (+5.66%) |
Aug 19, 2026 6w ago | Insider Cluster | $61.73 $61.80 | ▲ +0.11% | ▲ +0.50% | $57.16 (−7.40%) |
Aug 12, 2026 7w ago | 144 | $58.56 $60.58 | ▲ +3.45% | ▲ +5.41% | $57.16 (−2.39%) |
Aug 5, 2026 8w ago | 8-K | $57.75 $59.22 | ▲ +2.55% | ▲ +2.19% | $57.16 (−1.02%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
May 28, 2026 18w ago | Insider Cluster | $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $57.16 (+2.51%) |
May 28, 2026 18w ago | 8-K | $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $57.16 (+2.51%) |
May 22, 2026 19w ago | Insider Cluster | $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $57.16 (+4.88%) |
May 15, 2026 19w ago | Insider Cluster | $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $57.16 (+9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access